Pegcetacoplan 54 mg/mL, 15 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 54 mg/mL, 15 mg/mL

Reference Brands: Empaveli (USA/EU), Syfovre(USA/EU)

Category: Opthalmology

Pegcetacoplan is a targeted complement inhibitor that binds to complement protein C3, preventing its cleavage and downstream inflammatory effects. It is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy secondary to age-related macular degeneration (AMD). It helps reduce red blood cell destruction and slow retinal damage progression.

Product Description:

Pegcetacoplan is a pegylated peptide inhibitor that targets human complement components C3 and C3b, playing an important role in the treatment of diseases driven by excessive complement activation. By selectively binding to C3 and C3b, pegcetacoplan blocks the activation of the complement pathway, helping to reduce complement-mediated inflammation and cell destruction. This mechanism is particularly important in conditions where the immune system damages healthy cells and tissues.

Pegcetacoplan is primarily used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by the destruction of red blood cells. It is also approved in certain regions for the treatment of geographic atrophy associated with age-related macular degeneration. In addition, pegcetacoplan is being studied or used in conditions such as cold agglutinin disease and C3 glomerulopathy, where complement system dysregulation contributes to disease progression.

By targeting C3, a central component of the complement system and an essential part of the innate immune response, pegcetacoplan helps control abnormal immune activity and prevent tissue damage. This targeted approach provides a valuable therapeutic option for patients with complement-mediated disorders and related inflammatory diseases.